Sarepta Therapeutics (NASDAQ:SRPT) Downgraded to "Hold" Rating by TD Cowen

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) was downgraded by investment analysts at TD Cowen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Wednesday,Finviz reports. They currently have a $24.00 price target on the biotechnology company's stock. TD Cowen's target price suggests a potential upside of 11.32% from the company's previous close.

Other research analysts have also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft lowered their price objective on Sarepta Therapeutics from $50.00 to $25.00 and set a "hold" rating on the stock in a research report on Tuesday. Robert W. Baird lowered their price target on shares of Sarepta Therapeutics from $60.00 to $30.00 and set an "outperform" rating on the stock in a research report on Tuesday. Oppenheimer dropped their price objective on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. HC Wainwright lowered shares of Sarepta Therapeutics from a "neutral" rating to a "sell" rating in a research report on Monday. Finally, The Goldman Sachs Group cut shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating and set a $29.00 target price on the stock. in a report on Tuesday. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $72.04.

Sarepta Therapeutics Stock Up 3.0%

Shares of SRPT opened at $21.56 on Wednesday. The firm has a market cap of $2.12 billion, a P/E ratio of -8.01 and a beta of 0.61. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02. Sarepta Therapeutics has a 52 week low of $18.30 and a 52 week high of $173.25. The firm's 50-day simple moving average is $45.00 and its 200 day simple moving average is $84.80.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. Sarepta Therapeutics's revenue for the quarter was up 80.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.73 EPS. On average, analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. EP Wealth Advisors LLC increased its stake in shares of Sarepta Therapeutics by 2.2% in the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock valued at $606,000 after buying an additional 105 shares during the period. CIBC Asset Management Inc lifted its stake in shares of Sarepta Therapeutics by 5.1% in the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after acquiring an additional 139 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock valued at $352,000 after acquiring an additional 145 shares during the last quarter. Virtus ETF Advisers LLC boosted its holdings in Sarepta Therapeutics by 6.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,809 shares of the biotechnology company's stock valued at $342,000 after acquiring an additional 174 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its position in Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 194 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.